

ASX Release

19th September 2016

PHASE II CANINE TRIAL BEGINS AT THE UNIVERSITY OF CAMBRIDGE

First canine treated with reformulated MPL in capsules

PharmAust Limited ("PharmAust") (ASX: PAA) is pleased to report that the first canine with cancer has been recruited for the study and has started treatment with MPL capsules at the University of Cambridge, Department of Veterinary Sciences, The dog in question is suffering from metastatic mammary cancer.

The primary objective of the trial is to examine the effects of reformulated MPL capsules in different canine cancers with the aim of determining which cancers should be targeted in Phase III.

The canines in this study will have failed "standard of care" and will have few or no therapeutic options available. The Phase I canine trial undertaken in 2014/2015 showed excellent safety with suppression of tumour markers and the current Phase II is intended to build on these successful earlier results by including determinations of regression, stable disease or progression by measurement of tumour size.

The ease with which owners can administer MPL capsules will also be an important factor in the trial as the initial phase I trial was limited by palatability issues of the drug, which led to the development and manufacture of the capsules.

PharmAust's Chairman, Dr Roger Aston said: "Having initially demonstrated activity against cancer in man and canines, this Phase II study in dogs is a critical step as it is intended to show clinically relevant endpoints such as tumour size and growth or regression. Furthermore, a positive effect in canines will be a strong indication as to what can be expected in man. It is also noteworthy that most canine cancer drugs are essentially the same as those used in man with a modified dose."

As MPL is already approved for veterinary use by PharmAust's partner, Novartis Animal Health, we believe that if successful in this trial, MPL will be able to be approved quickly for the treatment of dog cancers following a further pivotal study.

We look forward to reporting progress when further animals are recruited and treated

For further details about PharmAust please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Mr Robert Bishop
Executive Director
Tel: 0417 445 180
robertbishop@pharmaust.com

About University of Cambridge

The University of Cambridge's mission is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It admits the very best and brightest students, regardless of background, and offers one of the UK's most generous bursary schemes. The University of Cambridge's reputation for excellence is known internationally and reflects the scholastic achievements of its academics and students, as well as the world-class original research carried out by its staff. Some of the most significant scientific breakthroughs occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history's greatest minds and has produced more Nobel Prize winners than any other UK institution with over 80 laureates.